Loading quotes...
Forecast
The analysts' average price target is 55,79€ (+1.323,21%). The median is 35,61€ (+808,42%).
| Buy |
5 |
| Hold |
13 |
| Sell |
2 |
News Go to news feed
Tilray Brands to buy HelloMD and build vertically integrated medical cannabis platform in Canada
Tilray Brands announced on June 29 that it will acquire HelloMD's Canadian medical cannabis assets after winning a court-approved sale process. The deal pairs HelloMD's digital telehealth and patient engagement platform with Tilray's cultivation, clinical expertise and national fulfillment to create a connected pathway for patients and practitioners. Tilray highlighted opportunities to expand into adjacent wellness categories like sleep and pain support; financial terms were not disclosed. Shares of Tilray are down more than 50% year-to-date. » More on finance.yahoo.com
Financials
| (EUR) | May 2026 | |
|---|---|---|
| Revenue | 241.83m | 10,93% |
| Gross profit | 72.39m | 11,49% |
| Net profit | −42.55m | 97,24% |
| EBITDA | 12.75m | 100,78% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 452.95m€ |
Number of shares | 111.83m |
52-week high/low | 19,91€ - 3,15€ |
| Dividends | No |
Beta | 1,91 |
P/E ratio | −3,54 |
PEG ratio | −0,02 |
P/B ratio | 0,33 |
P/S ratio | 0,46 |
Company profile
| Name | TILRAY BRANDS NEW O.N. |
| CEO | Irwin David Simon |
| Headquarters | Leamington,
on USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| Employees | 3.595 |
Deep Dive
Discover assets
Shareholders of TILRAY BRANDS NEW O.N. also invest in the following assets
